Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VIP943 (QW)
VIP943 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation of VIP943 (QW) | EXPERIMENTAL | Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration weekly (QW). |
| Dose Escalation of VIP943 (BIW) | EXPERIMENTAL | Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration twice weekly (BIW). |
| Name | Type | Description |
|---|---|---|
| VIP943 (QW) | DRUG | VIP943 will be administered by IV Infusion weekly |
| VIP943 (BIW) | DRUG | VIP943 will be administered by IV Infusion bi-weekly |
Inclusion Criteria: * Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies. * Evidence of ≥5% bone marrow or blood blasts (acute leukemia) or ≥5% bone marrow or blood myeloblasts (MDS) to ...
VIP943 is an investigational small molecule being studied for the treatment of acute myeloid leukemia, a cancer of the blood and bone marrow. It is also being evaluated in B-cell acute lymphoblastic leukemia and high-risk myelodysplastic syndrome. It is not approved for any indication and remains in clinical development.
VIP943 is being developed by Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company that trades under the ticker symbol VINC. Vincerx is the sponsor of the ongoing clinical program evaluating VIP943 in patients with advanced hematologic malignancies.
VIP943 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 1 program is designed to evaluate the drug in patients with advanced CD123-positive hematologic malignancies.
VIP943 is being studied in one active clinical trial, NCT06034275, titled Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies. The trial is currently recruiting and plans to enroll approximately 36 participants aged 18 years and older in the United States.
The NCT06034275 trial is enrolling patients with acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndrome. Enrollment targets approximately 36 adult participants across sites in the United States, and the study is currently recruiting.
Yes, VIP943 (QW) is an alternative name for VIP943, the investigational small molecule developed by Vincerx Pharma. Both names refer to the same compound being studied in the Phase 1 trial NCT06034275 for advanced CD123-positive hematologic malignancies.